CRVO

8-K - CervoMed Inc. (0001053691) (Filer)

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in "pure" DLB and support selection of 50 mg TID for planned Phase 3 study in DLB Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic target in DLB New Phase 2 study showed an 80 mg twice-daily dose of neflamapimod met its primary safety, tolerabi

EFFECT - CervoMed Inc. (0001053691) (Filer)

424B3 - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

Interim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a therapeutic target and support neflamapimod's potential to treat frontotemporal dementia (FTD) driven by tau pathology Nonfluent variant primary progressive aphasia (nfvPPA), the type of FTD most commonly associated with tau pathology, has no approved treatments in the United States or European Union BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the

SCHEDULE 13G/A - CervoMed Inc. (0001053691) (Subject)

S-3 - CervoMed Inc. (0001053691) (Filer)

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were $10 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net procee

8-K - CervoMed Inc. (0001053691) (Filer)

424B5 - CervoMed Inc. (0001053691) (Filer)

8-K - CervoMed Inc. (0001053691) (Filer)

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the o

8-K - CervoMed Inc. (0001053691) (Filer)

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, also known as "pure DLB". The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging,

DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As Wall Street increasingly rewards companies with differentiated technologies and clearly defined growth catalysts, here are four names that have emerged as closely watched stories spanning biotechnology, AI, aerospace, communications, and digital infrastructure. From neurodegenerative disease specialist CervoMed (NASDAQ: CRVO) advancing multiple late-stage neurological programs, to NeOnc Technologies (NASDAQ: NTHI) securing a significant international regulatory milestone for its brain cancer platform, investors continue searching for companies positioned ahead of potentially transformative clinical catalysts. At the same

DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. Download the 24/7 Market News App here https://app.247mnn.com/ or on the A

4 - CervoMed Inc. (0001053691) (Issuer)

8-K - CervoMed Inc. (0001053691) (Filer)

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026. Presentation DetailsFormat: Fireside ChatDate: Monday, June 15, 2026Time: 7:00 – 7:30 AM ETWebcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)

4 - CervoMed Inc. (0001053691) (Issuer)